tradingkey.logo

Caris Life Sciences lifts US IPO price range

ReutersJun 16, 2025 11:19 AM

- Cancer diagnostic firm Caris Life Sciences said on Monday it was targeting a valuation of $5.67 billion in its U.S. initial public offering, after raising its proposed price range.

The Irving, Texas-based company is marketing the IPO at a price range between $19 and $20 apiece, according to a regulatory filing. It is seeking up to $470.6 million.

BofA Securities, J.P. Morgan, Goldman Sachs and Citigroup are the lead underwriters.

Caris will start trading on the Nasdaq on Wednesday under the symbol 'CAI'.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI